Phibro Animal Health (NASDAQ:PAHC) Upgraded by StockNews.com to Strong-Buy Rating

StockNews.com upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a buy rating to a strong-buy rating in a report released on Thursday.

Several other analysts also recently issued reports on the company. Barclays upped their price target on Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 12th. Bank of America upped their target price on Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research report on Friday, August 30th. Finally, JPMorgan Chase & Co. began coverage on Phibro Animal Health in a report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $16.50.

Phibro Animal Health Stock Performance

PAHC stock opened at $23.59 on Thursday. The firm has a 50 day moving average of $23.30 and a two-hundred day moving average of $20.17. Phibro Animal Health has a 12 month low of $9.49 and a 12 month high of $25.98. The company has a market capitalization of $955.40 million, a price-to-earnings ratio of 54.86, a P/E/G ratio of 0.62 and a beta of 0.51. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, August 28th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. The firm had revenue of $273.16 million during the quarter, compared to analysts’ expectations of $262.44 million. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. As a group, equities analysts anticipate that Phibro Animal Health will post 1.61 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Wednesday, November 27th will be given a $0.12 dividend. This represents a $0.48 annualized dividend and a yield of 2.03%. The ex-dividend date of this dividend is Wednesday, November 27th. Phibro Animal Health’s dividend payout ratio is currently 111.63%.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, Director E Thomas Corcoran acquired 5,000 shares of Phibro Animal Health stock in a transaction dated Wednesday, September 4th. The stock was bought at an average cost of $20.02 per share, with a total value of $100,100.00. Following the completion of the transaction, the director now owns 25,000 shares of the company’s stock, valued at $500,500. The trade was a 25.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 50.07% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds have recently modified their holdings of PAHC. Price T Rowe Associates Inc. MD boosted its position in shares of Phibro Animal Health by 7.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,393 shares of the company’s stock valued at $200,000 after acquiring an additional 1,063 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in Phibro Animal Health by 56.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 79,667 shares of the company’s stock worth $1,030,000 after purchasing an additional 28,584 shares during the period. CWM LLC lifted its position in Phibro Animal Health by 89.8% in the second quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after purchasing an additional 1,035 shares during the period. Cardinal Capital Management lifted its position in Phibro Animal Health by 4.7% in the second quarter. Cardinal Capital Management now owns 56,027 shares of the company’s stock worth $940,000 after purchasing an additional 2,520 shares during the period. Finally, Summit Securities Group LLC bought a new position in Phibro Animal Health in the second quarter worth $83,000. 99.34% of the stock is owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.